Trial Profile
Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Fenretinide (Primary) ; Treosulfan (Primary) ; Zoledronic acid (Primary) ; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Granulocyte colony-stimulating factors; Ifosfamide; Melphalan; Mesna; Vincristine
- Indications Ewing's sarcoma
- Focus Therapeutic Use
- Acronyms EWING2008
- 16 Oct 2023 Results published in the Clinical Cancer Research
- 07 Jun 2022 Results of subgroup analysis assessing impact of adjuvant radiotherapy in patients with localized Ewing sarcoma at the extremities from this trial presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 15 Apr 2022 Results (n=109) assessing effect of treosulfan and melphalan high-dose chemotherapy (TreoMel-HDT) followed by reinfusion of autologous hematopoietic stem cells on event-free survival (EFS) and overall survival in high-risk Ewing sarcoma, published in the Journal of Clinical Oncology.